It is a good time to take another look at Theravance Biopharma shares, which are "undervalued and underappreciated," Cantor Fitzgerald analyst Louise Chen tells investors in a research note. The company successfully executed on its stated business objectives in 2019, setting it up for "strong momentum" into 2020 and beyond as it continues to expand on the commercial launches of Trelegy Ellipta and Yupelri as well as advance its "best-in-class" pipeline, contends the analyst. Chen believes "many potentially positive events" as well as data readouts that should drive the shares higher. She keeps an Overweight rating on Theravance Biopharma with a $55 price target.